Andere talen Mezzion Pharma Co.,Ltd.

Aandelen

A140410

KR7140410002

slotkoers Korea S.E. Andere beurzen 00:00:00 01-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
38.300 ^KRW	+3,23%		-1,42%	-1,79%

14/05	Mezzion Pharma Co. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
18/03	Mezzion Pharma Co. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Mezzion Pharma Co.,Ltd. announced that it has received KRW 49.99999719 billion in funding from BRV Capital Management and other investors	20-06-23
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
Mezzion Pharma to Raise 50 Billion Won From Share Sale	20-04-23
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 49.99999719 billion in funding from BRV Capital Management	19-04-23
Mezzion Pharma Co.,Ltd. Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects	21-02-23
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11-11-22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12-08-22
Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease	31-05-22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	11-05-22
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23-03-22
Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting	21-12-21
Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding	16-11-21
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding	12-11-21
Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations	15-06-21
Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease Has Been Accepted for Filing by the FDA	26-05-21
Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil	29-03-21
Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients	30-06-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mezzion Pharma Co.,Ltd.

Aandelen

A140410

KR7140410002

Andere talen

Filters